Login below, or create an account for free.
Below are some useful resources developed by other organisations.
This booklet was written to help you and your family navigate the complex system for accessing new blood cancer drugs in Australia, particularly ones that have not been funded on the Pharmaceutical Benefits Scheme. With thanks to the Leukaemia Foundation.
Dr Shalin has the confronting experience of having his genomes sequenced. What will the test reveal about the future of his health? An look into genetic sequencing and the exciting possibilities it presents.
The Unicorn Foundation NET Specialist Registry is a resource that acknowledges those medical practitioners who are experienced in the management of neuroendocrine cancers and who fulfill certain criteria that the Unicorn Foundation has applied.
Not every drug designed by pharmaceutical companies makes it to the market; very few do. Only 9.6% of new drugs in development in the years 2006-2015 successfully made it to the market to be used by patients.
Genomic medicine is the future for all cancer treatment, but will have its greatest impact for ‘rare’, high-mortality cancers.For more information about Genomic Medicine, click here
With thanks to Bristol-Myers Squibb.
Immuno-oncolgy uses the bodies own immune system to help fight cancer. With thanks to Bristol-Myers Squibb.
Dr. Dan Chen explains how immunotherapy may affect the PD-L1/PD-1 pathway, enabling the body to better detect and fight cancer.
Creating enabling policies to provide patients with an innovative cancer treatment modality. With thanks to The European Expert Group on Immuno-Oncology.
This link is to the National Cancer Institute (NCI) cancer website in the United States. There may be references to drugs and clinical trials that are not available here in Australia.
Stay up to date with the latest news including upcoming events, campaigns and announcements from Rare Cancers Australia.
Rare Cancers Australia Ltd (RCA) is a charity whose purpose is to improve awareness, support and treatment of Australians with rare and less common (RLC) cancers. In Australia in 2017, an estimated 52,000 people will be diagnosed with a RLC cancer and 25,000 will die from them, according to Cancer in Australia 2017 estimates.